John Hunt
Family Medicine · Kalamazoo, MINPI 1578532537
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,428 and has fallen 97.0% since, to $43 in 2024.
Across 159 payments — averaging $13.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$381
- Pfizer$270
- Amgen$147
- Boehringer Ingelheim$140
- GSK$124
- Takeda Pharmaceuticals U.S.A., Inc.$122
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $381 |
| Pfizer | 22 | $270 |
| Amgen | 10 | $147 |
| Boehringer Ingelheim | 11 | $140 |
| GSK | 20 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $122 |
| Johnson & Johnson | 6 | $82 |
| Merck | 6 | $74 |
| AbbVie(2 entities) | 4 | $71 |
| Lilly USA, LLC | 5 | $64 |
| Dexcom, Inc. | 3 | $57 |
| Novartis | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| AstraZeneca | 4 | $45 |
| Bristol Myers Squibb | 2 | $45 |
| Shire North American Group Inc | 3 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| Radius Health, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Gilead | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$2,199 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 20 | $407 |
| Irbesartan | 13 | $296 |
| Amlodipine Besylate | 23 | $211 |
| Omeprazole | 11 | $192 |
| Losartan Potassium | 18 | $173 |
| Metformin Hcl ErMetformin Hcl | 11 | $108 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kalamazoo
- Theresa KordishKalamazoo$87K
- Eric HouchinKalamazoo$59K
- James HuntKalamazoo$17K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.